Advertisement - Members don't see this ad
2027 CMS OPPS proposed rule: RO takeaways
I went through the 2027 OPPS proposed rule. This is hospital outpatient only—not the MPFS, not freestanding-center payment, and not a new RO Model.
The big picture is surprisingly favorable for conventional hospital-based RT, with a major exception for 340B theranostics.
1. Conventional hospital-based radiation may get a meaningful boost
CMS proposes:
Very rough conversion-factor effect:
But directionally, conventional HOPD radiation looks like a winner.
2. 340B theranostics takes a major hit
CMS proposes paying separately payable 340B-acquired drugs and radiopharmaceuticals at approximately:
This is most relevant to hospital theranostics programs using 340B inventory. The key question will become actual net acquisition cost, not just Medicare payment.
CMS also proposes mandatory claim-line identification:
Pass-through products and certain exempt hospitals, including rural sole community hospitals and PPS-exempt cancer hospitals, are excluded from the reduction.
3. Biology-guided RT gets cut about 15%
For ReFlexion/BgRT:
The rates are based on extremely thin claims volume:
This looks like the beginning of claims-based normalization after initial new-technology pricing.
4. Brachytherapy sources are mostly stable
CMS largely keeps the existing source-payment framework.
A few very low-volume sources receive explicit stabilization rather than being repriced from essentially meaningless claims samples.
Examples include:
No major redesign of HDR procedure payment appears in the rule. The changes are mainly about source pricing and low-volume volatility.
5. Expensive diagnostic radiopharmaceuticals remain separately payable
The diagnostic radiopharmaceutical packaging threshold rises slightly:
That is good for access, although 340B acquisition rules may still affect payment depending on the product and hospital.
CMS is also recalibrating nuclear-medicine APCs because expensive tracers are now paid separately. PET programs should therefore model the scan and radiopharmaceutical as separate revenue streams.
6. Off-campus hospital RT centers need to pay attention
CMS proposes PFS-equivalent payment for certain noncontrast imaging APCs performed in excepted off-campus departments.
Core RT simulation and planning APCs do not appear to be included, so CT simulation itself does not look directly targeted.
However, diagnostic CT or MRI performed at an off-campus cancer center may be affected.
More importantly, CMS proposes mandatory provider-based attestation for every off-campus outpatient department operating before January 1, 2028.
The filing window runs through the end of 2027. This is not optional paperwork; failure to attest can affect Medicare payment.
Hospital-owned satellite RT centers should confirm their status now rather than assume someone handled it years ago.
7. No major new RO quality or prior-authorization mandate
I did not find:
Practical summary by setting
Freestanding RO:
Little direct effect from this rule. Await the 2027 MPFS.
Hospital-based conventional RT:
Likely favorable, potentially substantially so.
Legacy 340B hospital:
Conventional RT benefits, but the broader cancer service line may lose drug margin.
Theranostics-heavy 340B program:
Probably the biggest loser.
BgRT center:
Direct approximately 15% cut.
Off-campus HOPD:
Audit diagnostic imaging exposure and provider-based attestation.
CMS is shifting a large amount of money from 340B drug reimbursement into non-drug outpatient services.
Radiation oncology happens to sit on the favorable side of that redistribution.
So for ordinary hospital-based external beam RT, 2027 could be quite good. For 340B theranostics programs, it could be a meaningful reset. Everything else is mostly incremental.
The rule is still proposed, and comments are due August 31, 2026.
I went through the 2027 OPPS proposed rule. This is hospital outpatient only—not the MPFS, not freestanding-center payment, and not a new RO Model.
The big picture is surprisingly favorable for conventional hospital-based RT, with a major exception for 340B theranostics.
1. Conventional hospital-based radiation may get a meaningful boost
CMS proposes:
- Routine OPPS update: +2.4%
- Additional budget-neutral increase to non-drug OPPS rates: +8.44%
Very rough conversion-factor effect:
- Hospitals not subject to the old 340B remedy clawback: approximately +11%
- Older hospitals subject to the proposed 3% clawback: approximately +7.7%
But directionally, conventional HOPD radiation looks like a winner.
2. 340B theranostics takes a major hit
CMS proposes paying separately payable 340B-acquired drugs and radiopharmaceuticals at approximately:
- ASP –33.4%, rather than ASP +6%
This is most relevant to hospital theranostics programs using 340B inventory. The key question will become actual net acquisition cost, not just Medicare payment.
CMS also proposes mandatory claim-line identification:
- JG: 340B and subject to reduction
- TB: 340B but exempt
- New modifier for non-340B acquisition
Pass-through products and certain exempt hospitals, including rural sole community hospitals and PPS-exempt cancer hospitals, are excluded from the reduction.
3. Biology-guided RT gets cut about 15%
For ReFlexion/BgRT:
- G0562, BgRT modeling: proposed payment approximately $1,650
- G0563, BgRT delivery per fraction: approximately $2,751
The rates are based on extremely thin claims volume:
- 24 claims for modeling
- 47 claims for delivery
This looks like the beginning of claims-based normalization after initial new-technology pricing.
4. Brachytherapy sources are mostly stable
CMS largely keeps the existing source-payment framework.
A few very low-volume sources receive explicit stabilization rather than being repriced from essentially meaningless claims samples.
Examples include:
- Planar Pd-103
- Therapeutic I-125 sodium iodide
- Linear non-stranded Pd-103
No major redesign of HDR procedure payment appears in the rule. The changes are mainly about source pricing and low-volume volatility.
5. Expensive diagnostic radiopharmaceuticals remain separately payable
The diagnostic radiopharmaceutical packaging threshold rises slightly:
- $655 → $665 per day
That is good for access, although 340B acquisition rules may still affect payment depending on the product and hospital.
CMS is also recalibrating nuclear-medicine APCs because expensive tracers are now paid separately. PET programs should therefore model the scan and radiopharmaceutical as separate revenue streams.
6. Off-campus hospital RT centers need to pay attention
CMS proposes PFS-equivalent payment for certain noncontrast imaging APCs performed in excepted off-campus departments.
Core RT simulation and planning APCs do not appear to be included, so CT simulation itself does not look directly targeted.
However, diagnostic CT or MRI performed at an off-campus cancer center may be affected.
More importantly, CMS proposes mandatory provider-based attestation for every off-campus outpatient department operating before January 1, 2028.
The filing window runs through the end of 2027. This is not optional paperwork; failure to attest can affect Medicare payment.
Hospital-owned satellite RT centers should confirm their status now rather than assume someone handled it years ago.
7. No major new RO quality or prior-authorization mandate
I did not find:
- A new RO-specific OQR measure
- A new external-beam coding overhaul
- Addition of RT to the OPPS prior-authorization program
- A new RO Model
Practical summary by setting
Freestanding RO:
Little direct effect from this rule. Await the 2027 MPFS.
Hospital-based conventional RT:
Likely favorable, potentially substantially so.
Legacy 340B hospital:
Conventional RT benefits, but the broader cancer service line may lose drug margin.
Theranostics-heavy 340B program:
Probably the biggest loser.
BgRT center:
Direct approximately 15% cut.
Off-campus HOPD:
Audit diagnostic imaging exposure and provider-based attestation.
CMS is shifting a large amount of money from 340B drug reimbursement into non-drug outpatient services.
Radiation oncology happens to sit on the favorable side of that redistribution.
So for ordinary hospital-based external beam RT, 2027 could be quite good. For 340B theranostics programs, it could be a meaningful reset. Everything else is mostly incremental.
The rule is still proposed, and comments are due August 31, 2026.
